Research Lab Results
-
Frueh Laboratory
The Frueh Laboratory uses nuclear magnetic resonance (NMR) to study how protein dynamics can be modulated and how active enzymatic systems can be conformed. Non-ribosomal peptide synthetases (NRPS) are large enzymatic systems that biosynthesize secondary metabolites, many of which are used by pharmaceutical scientists to produce drugs such as antibiotics or anticancer agents. Dr. Frueh's laboratory uses NMR to study inter- and intra-domain modifications that occur during the catalytic steps of NRPS. Dr. Frueh and his team are constantly developing new NMR techniques to study these complicated enzymatic systems. -
Jonathan Walsh Lab
The Jonathan Walsh Lab is currently researching longitudinal trends of diagnostic and procedural utilization in pediatric patients with head and neck complaints. -
Ashish Nimgoankar Lab
The Ashish Nimgoankar Lab is interested in translational technology development and image-guided therapies. -
Our mission is to reveal the molecular logic of our intelligence in health and disease. We use advanced molecular biological tools and state-of-the-art neuroscience to test the role of synaptic and neuronal molecules in the dynamics of the living brain.
Artificial neural networks have been heavily inspired by the brain’s architecture, guiding our journey to discovering the keys to intelligence. We now find ourselves at a pivotal moment: today's AI systems surpass biological circuits in certain tasks, yet we still lack a fundamental understanding of the mechanisms behind the brain’s superior cognitive flexibility and efficiency. At Ingie Hong’s Quantitative Intelligence Lab, we are dedicated to unraveling the principles that enable the mammalian cortex to achieve remarkable feats of intelligence, including rapid learning, generalization, and inference across vast stores of memory.
A single neuron’s response depends on its synaptic connections and intrinsic properties, which are dictated by the expression of neuronal genes. However, the role of these molecules in brain computations remains largely uncharted territory. Focusing on the mouse visual cortex as a starting point for broader generalization, and using large-scale electrophysiology, advanced microscopy, and machine learning, we have begun to uncover the impact of key synaptic genes on cortical processing and their role in the brain’s “working algorithm” (Hong et al., Nature, 2024). Our molecular tools, including gene therapy vectors and antisense oligonucleotides, show promise as effective therapeutic candidates.
Our research will advance the nascent field of 'neurocomputational therapeutics'—innovative genetic and pharmacological tools that address biases in neural activity. These tools will not only facilitate the development of novel mechanism-based treatments for brain disorders but also inspire the next generation of intelligent artificial neural networks.
-
Ami Shah Lab
Researchers in the Ami Shah Lab study scleroderma and Raynaud’s phenomenon. We examine the relationship between cancer and scleroderma, with a focus on how and if cancer causes scleroderma to develop in some patients. We are currently conducting clinical research to study ways to detect cardiopulmonary complications in patients with scleroderma, biological and imaging markers of Raynaud’s phenomenon, and drugs that improve aspects of scleroderma. -
Bakker Memory Lab
Research in the Bakker Memory Laboratory is focused on understanding the mechanisms and brain networks underlying human cognition with a specific focus on the mechanisms underlying learning and memory and the changes in memory that occur with aging and disease. We use a variety of techniques including neuropsychological assessments, experimental behavioral assessments and particularly advanced neuroimaging methods to study these questions in young and older adults and patients with mild cognitive impairment, Alzheimer’s disease, Parkinson’s disease and epilepsy. Through our collaborations with investigators in both basic science and clinical departments, including the departments of Psychiatry and Behavioral Sciences, Psychological and Brain Sciences, Neurology and Public Health, our research also focuses on brain systems involved in spatial navigation and decision-making as well as cognitive impairment in neuropsychiatric conditions such as schizophrenia, eating disorders, obsessive-compulsive disorders, depression and anxiety. -
Zanvyl Krieger Mind/Brain Institute
The Zanvyl Krieger Mind/Brain Institute is dedicated to the study of the neural mechanisms of higher brain functions using modern neurophysiological, anatomical and computational techniques. Our researchers use various approaches to understand information processing and its influence on perception, memory, abstract thought, complex behavior and consciousness. Systems and cognitive laboratories use neurophysiology, brain imaging and psychophysics to develop a quantitative, network-level understanding of cognitive information processing. Other researchers use analytical approaches such as system identification, dimensionality reduction, information theory and network modeling to understand information processing. Other areas of research in the Institute include the study of how visual and tactile information processing leads to perception and understanding of two- and three-dimensional objects. Another focus is on neural processing and recognition of speech and other complex sounds. Still other laboratories study neural mechanisms of attention, memory formation, motor learning, decision-making and executive control of behavior. -
Daniel Weinberger Laboratory
The Daniel Weinberger Laboratory focuses on the neurobiological mechanisms of genetic risk for developmental brain disorders. We study the genetic regulation of the transcriptome in normal human brain across the human life span and in brains from patients with various psychiatric disorders. We also study the impact of genetic variation on aspects of human brain development and function linked with risk for schizophrenia and related psychiatric disorders. Our lab uses unique molecular and clinical datasets and biological materials from a large sample of families with affected and unaffected offspring and normal volunteers. These datasets include DNA, lymphoblast and fibroblast cell lines, and extensive quantitative phenotypes related to genetic risk for schizophrenia, including detailed cognitive assessments and various neuroimaging assays. In other research, we are working on a human brain transcriptome project that is RNA sequencing over 1,000 human brain samples in various regions and based also on sorting of specific celliular phentypes. We are exploring the molecular processing of the gene and its implications for cognition and aspects of human temperament. -
Wu Lab
Dr. Wu leads a multi-disciplinary team with collaborators from the Bloomberg School of Public Health, JHU Whiting School of Engineering, and JHU Krieger School of Arts and Sciences. She conducts ongoing investigations with the Multicenter AIDS Cohort Study and Women’s Inter-agency Health Study. Her lab’s goals are to develop, implement, and validate novel imaging-based metrics of cardiac structure and function to improve risk prediction and stratification at the individual patient-level. Research Focuses: Predictors of Sudden Cardiac Death by Magnetic Resonance Imaging Subclinical myocardial disease in people living with HIV Individualized risk prediction Cardiac structural and mechanical modeling -
Venu Raman Research Lab
The Raman laboratory is within the Division of Cancer Imaging Research in the Department of Radiology and Radiological Science. The focus of the laboratory is bench-to-bed side cancer research. We integrate molecular and cellular biology, developmental biology, cancer biology, molecular imaging techniques to study cancer formation and progression. Many of the projects in the lab investigate dysregulated genes in cancer and the translatability of this information to a clinical setting. One such project is to functionally decipher the role of a RNA helicase gene, DDX3, in the biogenesis of multiple cancer types such as breast, lung, brain, sarcoma, colorectal and prostate. Additionally, using a rational drug design approach, a small molecule inhibitor of DDX3 (RK-33) was synthesized and its potential for clinical translation is being investigated.